Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Despite Co-Diagnostics' potential, a massive price run-up has made CODX stock much less attractive.
The post Co-Diagnostics Stock Is an Interesting But Overpriced Pandemic Pick appeared first on InvestorPlace.

Co-Diagnostics Stock Is an Interesting But Overpriced Pandemic Pick

Co-Diagnostics, Inc. (CODX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Co-Diagnostics, Inc. (CODX) Moves to Strong Buy: Rationale Behind the Upgrade

Co-Diagnostics Inc. (NASDAQ: CODX) traded for less than $1.00 late last year.

Co-Diagnostics Stock Is Not a Penny Stock Anymore

ProShares Long Online/Short Stores ETF

CrowdStrike

Domino's Pizza

Emergent BioSolutions

JD.com

Vaxart

Zoom Video

Inside the top-performing sectors of Q1 and their winning stocks.

Top Sectors of Q1 & Their Winning Stocks

Novavax

Trillium Therapeutics

These stocks have soared while the overall market tanked. But are they buys?

The 3 Most Resilient Stocks in the Bear Market Today

As a near-term speculation, CODX stock might not be appropriate. But in the bigger picture, the coronavirus has taught harsh lessons to nearly every country, making Co-Diagnostics as relevant as it's ever been.

Co-Diagnostics Stock Is a Long-term Play in Disguise

Benzinga Pro's Stocks To Watch For Thursday: Co-Diagnostics (CODX) The company is a provider of reagents used for diagnostic tests and has been considered by traders one of the earliest plays on coronavirus testing.

Benzinga Pro's Stock To Watch For Thurs., Mar. 26, 2020: Co-Diagnostics (CODX)

ARK Genomic Revolution Multi-Sector ETF

Aytu BioScience

VanEck Vectors Biotech ETF

Loncar Cancer Immunotherapy ETF

Forty Seven Inc

iShares Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Vir Biotechnology

Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.

Coronavirus Scare Supports These Biotech ETFs & Stocks

While doubts abound on the various economic interventions in play or in plan, the same can’t be said for coronavirus-play CODX stock.
The post Why Virus-Play CODX Stock Isn’t a Long-Term Cure for Ailing Portfolios appeared first on InvestorPlace.

Why Virus-Play CODX Stock Isn’t a Long-Term Cure for Ailing Portfolios

QuidelOrtho Corp

Point-of-care testing enables better patient triage, bed management, and patient care decisions. Here are three stocks to benefit as demand rises.

Coronavirus Test Kit Demand to Drive These 3 Stocks

Is  (CODX) Outperforming Other Medical Stocks This Year?

Has Co-Diagnostics (CODX) Outpaced Other Medical Stocks This Year?

Inovio Pharmaceuticals

MannKind

An overall market rebound and some company-specific news are lighting a fire beneath these stocks.

Why 4 Coronavirus-Focused Stocks Are Crushing It Today

Co-Diagnostics Inc (NASDAQ: CODX) shares were rallying Tuesday following an update from the company regarding its COVID-19 test.

Co-Diagnostics Sees 'Aggressive Expansion' In Coronavirus Test Distribution After FDA Policy Revision

Moderna

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

We have picked biotech companies that are widely expected to develop a vaccine for the coronavirus and fight off the worst stock market carnage since the 2008 financial crisis.

4 Top Biotech Stocks to Buy in the Time of Coronavirus

Altimmune

Clorox

Quest Diagnostics

Gilead Sciences

Lakeland Industries

NanoViricides

Markets looked like they would be crushed yet again on Monday despite the emergency Federal Reserve rate cut announced on Sunday.

How Coronavirus Stocks Were Holding Up in Monday’s Sell-Off

Allied Healthcare Products

Costco

SPDR Dow Jones Industrial Average ETF

Invesco QQQ

SPDR S&P 500 ETF Trust

Walmart

Consumer Staples Select Sector SPDR Fund

Health Care Select Sector SPDR Fund

These two sectors lost lesser than the broader market during the 2008 financial crisis and may help you to tide over the latest virus crisis.

Beat Virus With 2 Sector ETFs & Stocks That Survived 2008 Crisis

Markets were crushed again on Thursday after President Trump announced a travel ban to Europe on Wednesday night.

How Coronavirus Stocks Responded to Thursday’s Sell-Off

Alpha Pro Tech

These three healthcare stocks are surging this morning after another day of bad news regarding the SARS-CoV-2 pandemic.

Why Alpha Pro Tech, Co-Diagnostics, and Inovio Pharmaceuticals Are on Fire Today

COVID-19 has rocked markets and caused panic across the world. While investors are feeling the pain as global supply chains may become constricted, playing on COVID-19 stocks has proven very lucrative.

Coronavirus Stocks See Rising Tide in Short Interest

GenMark Diagnostics

OPKO Health

It is worthwhile to keep an eye on stocks of companies that are engaged in the prevention, diagnosis and treatment of the disease.

4 Stocks to Gain the Most From the Coronavirus Outbreak

Buckle

Chipotle

Trump floats financial aids to counter the impact of the coronavirus outbreak. Notable stimulus measures include payroll tax cut, aid for wage earners and an emergency funding worth $8.3 billion

5 Stocks to Win Big From Trump's Economic Stimulus

As of late, it has definitely been a great time to be an investor in Co-Diagnostics, Inc. (CODX).

Co-Diagnostics, Inc. (CODX) Shares March Higher, Can It Continue?

AnaptysBio

A pair of black swans crushed these three healthcare stocks today.

Why AnaptysBio, Co-Diagnostics, and Novavax Are Getting Crushed Today

Thanks to the need for coronavirus testing, CODX stock has plenty of upside potential – in the near term. Because of its likely ephemeral trajectory, be sure to have your finger on the trigger if you’re going to speculate on it.

How High Can Virus Concerns Take CODX Stock?

Royal Caribbean Cruises

Keep an eye on these stocks during the COVID-19 crisis -- there might be a massive profit opportunity.

2 High-Risk, High-Reward Stocks to Add to Your Watchlist

News for Co-Diagnostics Stock (CODX)